Af­ter ovar­i­an can­cer flop, Phar­ma­Mar's lur­binecte­din makes the cut in small cell lung can­cer

More than a year af­ter its ex­per­i­men­tal drug, lur­binecte­din, failed a late-stage test in plat­inum-re­sis­tant ovar­i­an can­cer pa­tients, Span­ish biotech Phar­ma­Mar on Mon­day said the agent met the main goal in pa­tients with re­lapsed small cell lung can­cer (SCLC) in a Phase II study.

The pri­ma­ry end­point of the 105-pa­tient tri­al was to mea­sure the over­all re­sponse rate, while sec­ondary goals in­clud­ed pro­gres­sion-free sur­vival and over­all sur­vival. De­tailed study da­ta will be pro­vid­ed at a fu­ture med­ical meet­ing, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.